×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Laurus Labs Limited | 14542.7 | 1579.4 | 14327.5 | 2.93 | 48,325 | 95.0 |
| GLAXOSMITHKLINE PHARMACEUTICAL | 8485.9 | 2047.0 | 8048.3 | 12.08 | 47280 | 49.9 |
| Cohance Lifesciences Limited | 4966.8 | 525.7 | 4835.8 | 1.37 | 38752 | 110.0 |
Laurus Labs Limited, with Security Code 540222, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,279.3 | 1,107.7 | 1,158.0 | 1,132.2 | 1,414.5 | 1,116.9 | 1,184.9 | 1,265.2 | 1,650.0 | 1,432.8 |
| Expenses | 1,026.9 | 979.8 | 977.5 | 961.8 | 1,143.4 | 955.5 | 1,003.0 | 1,058.9 | 1,255.1 | 1,105.4 |
| Operating Profit | 252.4 | 127.9 | 180.5 | 170.4 | 271.1 | 161.4 | 181.8 | 206.3 | 394.9 | 327.4 |
| OPM % | 19.73% | 11.55% | 15.59% | 15.05% | 19.17% | 14.45% | 15.35% | 16.3% | 23.93% | 22.85% |
| Other Income | 5.9 | 6.7 | 5.9 | 10.7 | 24.1 | 9.3 | 11.9 | 7.1 | 72.2 | 21.5 |
| Interest | 41.0 | 33.5 | 37.8 | 37.6 | 42.0 | 40.9 | 44.7 | 48.0 | 48.6 | 43.9 |
| Depreciation | 80.6 | 83.9 | 85.4 | 86.8 | 88.9 | 91.0 | 90.9 | 88.7 | 88.2 | 93.6 |
| Profit before tax | 136.8 | 17.2 | 63.2 | 56.7 | 164.3 | 38.8 | 58.1 | 76.7 | 330.3 | 211.4 |
| Tax % | -25.2% | -24.2% | -26.2% | -24.8% | -26.2% | -25.8% | -26.9% | -25.4% | -23.7% | 25.3% |
| Net Profit | 102.3 | 13.1 | 46.7 | 42.6 | 121.3 | 28.8 | 42.4 | 57.3 | 251.9 | 157.9 |
| EPS in Rs | 1.88 | 0.48 | 0.87 | 0.79 | 2.25 | 0.53 | 0.79 | 1.06 | 0 | 2.93 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,544.8 | 1,380.9 | 1,181.8 | 1,224.5 | 1,194.9 | 1,439.7 | 1,194.9 | 1,223.7 | 1,415.1 | 1,720.3 |
| Expenses | 1,141.8 | 1,097.3 | 1,016.7 | 1,038.8 | 1,015.3 | 1,198.5 | 1,023.7 | 1,045.4 | 1,129.9 | 1,300.8 |
| Operating Profit | 403.1 | 283.6 | 165.1 | 185.7 | 179.6 | 241.2 | 171.2 | 178.3 | 285.2 | 419.5 |
| OPM % | 26.09% | 20.54% | 13.97% | 15.16% | 15.03% | 16.75% | 14.33% | 14.57% | 20.15% | 24.39% |
| Other Income | 1.4 | 1.7 | 3.6 | 1.8 | 2.4 | 18.5 | 2.5 | 4.6 | 9.4 | 58.6 |
| Interest | 42.7 | 53.1 | 39.2 | 42.4 | 50.8 | 50.5 | 49.2 | 52.6 | 57.8 | 56.4 |
| Depreciation | 84.4 | 87.0 | 90.6 | 93.4 | 98.4 | 102.3 | 106.1 | 107.5 | 106.1 | 110.4 |
| Profit before tax | 277.3 | 145.2 | 39.0 | 51.7 | 32.8 | 107.0 | 18.5 | 22.8 | 130.7 | 311.3 |
| Tax % | -26.9% | -27.1% | -30% | -27% | -27.3% | -29.8% | -33.9% | -22.3% | -30.7% | -25.1% |
| Net Profit | 202.5 | 105.3 | 26.8 | 37.1 | 23.3 | 75.0 | 12.7 | 20.0 | 92.9 | 232.8 |
| EPS in Rs | 3.76 | 1.9 | 0.46 | 0.68 | 0.43 | 1.4 | 0.23 | 0.37 | 1.71 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 3% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 7% |
| 3 Years: | -20% |
| TTM: | 70% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 45% |
| 3 Years: | 1% |
| 1 Year: | 29% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 14% |
| 3 Years: | 4% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 7% |
| 3 Years: | -24% |
| TTM: | 122% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 45% |
| 3 Years: | 1% |
| 1 Year: | 29% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|